Flunixin Meglumine

Names

[ Name ]:
Flunixin Meglumine

[Synonym ]:
Flunixin meglumine
MFCD01725419
2-{[2-Methyl-3-(trifluoromethyl)phenyl]amino}nicotinic acid - 1-deoxy-1-(methylamino)-D-glucitol (1:1)
EINECS 255-836-0
3-pyridinecarboxylic acid, 2-[[2-methyl-3-(trifluoromethyl)phenyl]amino]-, compd. with D-glucitol, 1-deoxy-1-(methylamino)- (1:1)
FLUNIXIN N-METHYLGLUCAMINE
2-[[2-Methyl-3-(trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic acid meglumine salt Banamine
2-{[2-methyl-3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid - 1-deoxy-1-(methylamino)-D-glucitol (1:1)
Flunixin (meglumine)

Biological Activity

[Description]:

Flunixin Meglumine is a potent inhibitor of COX used as analgesic agent with anti-inflammatory and antipyretic activity. Target: COXFlunixin meglumine is a potent, non-narcotic, non-steroidal analgesic agent with anti-inflammatory and antipyretic activity. It is a potent inhibitor of the enzyme cyclooxygenase. Flunixin meglumine therapy significantly (P less than or equal to 0.05) reduced rectal temperatures and quarter signs of inflammation and improved clinically graded depression when compared with these signs in saline solution-treated controls [1]. Flunixin meglumine was selective inhibitor of COX-1. Carprofen inhibited LPS-induction of iNOS. Carprofen and, to a lesser degree, flunixin meglumine had inhibitory effects on NFκB activation [2].

[Related Catalog]:

Research Areas >> Inflammation/Immunology

[Target]

COX-2:0.4 nM (IC50)

COX-1:17 nM (IC50)

[References]

[1]. Cheng Z, et al. Measurement of cyclooxygenase inhibition in vivo: a study of two non-steroidal anti-inflammatory drugs in sheep. Inflammation. 1998 Aug;22(4):353-66.

[2]. Bryant, C.E., B.A. Farnfield, and H.J. Janicke, Evaluation of the ability of carprofen and flunixin meglumine to inhibit activation of nuclear factor kappa B. Am J Vet Res, 2003. 64(2): p. 211-5.

[Related Small Molecules]

Chemical & Physical Properties

[ Density]:
1.403 g/cm3

[ Boiling Point ]:
378.7ºC at 760 mmHg

[ Melting Point ]:
136-138ºC

[ Molecular Formula ]:
C₂₁H₂₈F₃N₃O₇

[ Molecular Weight ]:
491.458

[ Flash Point ]:
182.8ºC

[ Exact Mass ]:
491.187927

[ PSA ]:
175.40000

[ LogP ]:
0.95620

[ Storage condition ]:
0-6°C

[ Water Solubility ]:
H2O: freely soluble | soluble

MSDS

Click to get detail MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: LZ4367000

CHEMICAL NAME :: D-Glucitol, 1-deoxy-1-(methylamino)-, 2-((2-methyl-3-(trifluoromethyl)phenyl)amino)-3- pyridinecarboxylate (salt)

CAS REGISTRY NUMBER :: 42461-84-7

LAST UPDATED :: 199403

DATA ITEMS CITED :: 1

MOLECULAR FORMULA :: C14-H11-F3-N2-O2.C7-H17-N-O5

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - domestic

DOSE/DURATION :: 39600 ug/kg/12D-I

TOXIC EFFECTS :: Behavioral - food intake (animal) Gastrointestinal - ulceration or bleeding from stomach

REFERENCE :: JAVMA4 Journal of the American Veterinary Medical Association. (American Veterinary Medical Assoc., 930 N. Meacham Rd., Schaumburg, IL 60196) V.48- 1915- Volume(issue)/page/year: 202,71,1993

Safety Information

[ Symbol ]:

GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H315-H319-H335

[ Precautionary Statements ]:
P261-P305 + P351 + P338

[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Gloves

[ Hazard Codes ]:
Xi:Irritant

[ Risk Phrases ]:
R36/37/38

[ Safety Phrases ]:
S26-S36

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
3

[ RTECS ]:
LZ4367000

Articles

Pharmacokinetics and effects on thromboxane B2 production following intravenous administration of flunixin meglumine to exercised thoroughbred horses.

J. Vet. Pharmacol. Ther. 38 , 313-20, (2015)

Flunixin meglumine is commonly used in horses for the treatment of musculoskeletal injuries. The current ARCI threshold recommendation is 20 ng/mL when administered at least 24 h prior to race time. I...

Gene expression analyses identify Narp contribution in the development of L-DOPA-induced dyskinesia.

J. Neurosci. 35(1) , 96-111, (2015)

In Parkinson's disease, long-term dopamine replacement therapy is complicated by the appearance of L-DOPA-induced dyskinesia (LID). One major hypothesis is that LID results from an aberrant transcript...

Registered report: the microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.

Elife 4 , e06434, (2015)

The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by conducting replications of selected experiments from a number of high-prof...